Company news

Caribou Biosciences, Inc. news in 2024

Caribou Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 5, 2024

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

September 24, 2024

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

September 2, 2024

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

August 11, 2024

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

July 8, 2024

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2024

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

May 29, 2024

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2024

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

April 14, 2024

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

April 3, 2024

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 10, 2024

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

March 4, 2024

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

January 6, 2024

Decks in 2024